Letonya - Letonca - Zāļu valsts aģentūra

opella healthcare france s.a.s., france - aluminii hydroxidum, magnija hydroxidum - suspensija iekšķīgai lietošanai - 40 mg/35 mg/ml

Letonya - Letonca - Zāļu valsts aģentūra

opella healthcare france s.a.s., france - aluminii hydroxidum, magnija hydroxidum - suspensija iekšķīgai lietošanai - 460 mg/400 mg/4,3 ml

Letonya - Letonca - Zāļu valsts aģentūra

opella healthcare france s.a.s., france - aluminii hydroxidum, magnija hydroxidum - košļājamā tablete - 400 mg/400 mg

Letonya - Letonca - Zāļu valsts aģentūra

baxter latvia, sia, latvia - mitoksantrona hidrohlorīds - koncentrāts infūziju šķīduma pagatavošanai - 2 mg/ml

Letonya - Letonca - Zāļu valsts aģentūra

dr. august wolff gmbh & co. kg arzneimittel, germany - urīnviela - krēms - 120 mg/g

Letonya - Letonca - Zāļu valsts aģentūra

baxter latvia, sia, latvia - mitoksantrona hidrohlorīds - koncentrāts infūziju šķīduma pagatavošanai - 2 mg/ml

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

accord healthcare s.l.u. - pegfilgrastim - neitropēnija - imunitātes stimulatori, - ilguma samazināšanās neutropenia un biežums pacientiem drudža neutropenia ārstēti ar citotoksiskas ķīmijterapijas ļaundabīgo audzēju (izņemot myeloid hroniskas leikēmijas un myelodysplastic sindromi).

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - neitropēnija - imunitātes stimulatori, - lai samazinātu ilgums neutropenia un sastopamība febrila neutropenia sakarā ar ķīmijterapiju.

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

pfizer europe ma eeig  - pegfilgrastim - neitropēnija - imunitātes stimulatori, - ilguma samazināšanās neutropenia un saslimstība ar pieaugušiem pacientiem drudža neutropenia ārstēti ar citotoksiskas ķīmijterapijas ļaundabīgo audzēju (izņemot myeloid hroniskas leikēmijas un myelodysplastic sindromi).

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doksorubicīns - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.